[Bone loss induced by GnRHa treatment in women].
The hypoestrogenic state induced by gonadotropin-releasing hormone agonist(GnRHa) has been shown to be effective in the treatment of uterine leiomyoma and endometriosis but to induce bone loss. The BMD significantly decreased from baseline(-4.9 +/- 2.5%, mean +/- SD) after 24 weeks of treatment of leuprolide acetate depot(p < 0.01), and remained significantly below the baseline(-3.4 +/- 2.7%, p < 0.01) at 12 months after the treatment period. To minimize bone loss without compromising efficacy, several investigators have sought to 'add-back' sex-steroid hormones or other bone-sparing agents. Unresolved issues from these studies include ideal regimens and whether the add-back therapy prevents bone loss without compromising efficacy. GnRHa plus oral bisphosphonate therapy prevents bone loss without deteriorating the therapeutic effect of GnRHa.
Matsuo
Hiroya
H
Department of Maternity Nursing, Faculty of Health Sciences, Kobe University School of Medicine.
D004164:Diphosphonates / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D011374:Progesterone / Q000008:administration & dosage
D004164:Diphosphonates; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; C083781:LHRH, Ala(6)-Gly(10)-ethylamide-